$MEIP
MEI Pharma, Inc.

2017 Q4 Form 10-Q Financial Statement

#000119312518035521 Filed on February 08, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2016 Q4
Revenue $358.0K $17.20M
YoY Change -97.92%
Cost Of Revenue $728.0K $1.771M
YoY Change -58.89%
Gross Profit -$370.0K $15.43M
YoY Change -102.4%
Gross Profit Margin -103.35% 89.7%
Selling, General & Admin $2.360M $1.970M
YoY Change 19.8% 1.03%
% of Gross Profit 12.77%
Research & Development $3.444M $1.642M
YoY Change 109.74% -48.4%
% of Gross Profit 10.64%
Depreciation & Amortization $20.00K $20.00K
YoY Change 0.0% 100.0%
% of Gross Profit 0.13%
Operating Expenses $3.444M $1.642M
YoY Change 109.74% -67.97%
Operating Profit -$6.172M $11.82M
YoY Change -152.23% -330.47%
Interest Expense $90.00K $70.00K
YoY Change 28.57% 133.33%
% of Operating Profit 0.59%
Other Income/Expense, Net
YoY Change
Pretax Income -$6.080M $11.89M
YoY Change -151.14% -333.14%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$6.079M $11.89M
YoY Change -151.15% -332.99%
Net Earnings / Revenue -1698.04% 69.1%
Basic Earnings Per Share -$0.16 $0.32
Diluted Earnings Per Share -$0.16 $0.32
COMMON SHARES
Basic Shares Outstanding 37.41M 37.17M shares
Diluted Shares Outstanding 37.41M 37.22M shares

Balance Sheet

Concept 2017 Q4 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.40M $55.20M
YoY Change -23.19% 2.6%
Cash & Equivalents $7.339M $15.05M
Short-Term Investments $35.10M $40.10M
Other Short-Term Assets $800.0K $2.700M
YoY Change -70.37% 237.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $43.21M $57.82M
YoY Change -25.27% 5.95%
LONG-TERM ASSETS
Property, Plant & Equipment $40.00K $40.00K
YoY Change 0.0% -28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $354.0K $388.0K
YoY Change -8.76% -11.62%
TOTAL ASSETS
Total Short-Term Assets $43.21M $57.82M
Total Long-Term Assets $354.0K $388.0K
Total Assets $43.57M $58.21M
YoY Change -25.16% 5.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.089M $382.0K
YoY Change 185.08% -14.73%
Accrued Expenses $3.230M $2.938M
YoY Change 9.94% 0.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.209M $3.320M
YoY Change 56.9% -1.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.209M $3.320M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $5.200M $3.300M
YoY Change 57.58% -2.94%
SHAREHOLDERS EQUITY
Retained Earnings -$189.2M -$169.4M
YoY Change 11.7% 2.13%
Common Stock $227.6M $224.3M
YoY Change 1.46% 3.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.36M $54.89M
YoY Change
Total Liabilities & Shareholders Equity $43.57M $58.21M
YoY Change -25.16% 5.81%

Cashflow Statement

Concept 2017 Q4 2016 Q4
OPERATING ACTIVITIES
Net Income -$6.079M $11.89M
YoY Change -151.15% -332.99%
Depreciation, Depletion And Amortization $20.00K $20.00K
YoY Change 0.0% 100.0%
Cash From Operating Activities -$4.750M -$3.740M
YoY Change 27.01% -11.58%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.970M $5.010M
YoY Change -0.8% 24950.0%
Cash From Investing Activities $4.970M $5.000M
YoY Change -0.6% 24900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 170.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -4.750M -3.740M
Cash From Investing Activities 4.970M 5.000M
Cash From Financing Activities 170.0K 0.000
Net Change In Cash 390.0K 1.260M
YoY Change -69.05% -129.93%
FREE CASH FLOW
Cash From Operating Activities -$4.750M -$3.740M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$4.750M -$3.740M
YoY Change 27.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37052361 shares
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15050000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37052000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37052000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2758956 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.84
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5462746 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.11
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189198000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43567000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
890000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1089000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
38358000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
227556000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Contractual Obligation
ContractualObligation
1300000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5209000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3230000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
43213000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
946930
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7339000
CY2017Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
42441000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2800000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
35102000
CY2017Q4 us-gaap Assets
Assets
43567000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
314000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
772000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1680120
CY2017Q4 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
150000000
CY2017Q4 meip Accrued Milestone Payments
AccruedMilestonePayments
0
CY2017Q4 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
75200000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10837000
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36772000 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36772000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4259083 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.21
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174331000
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55704000
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
996000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
585000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
50838000
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
225169000
CY2017Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4866000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3285000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
55323000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8458000
CY2017Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
53565000
CY2017Q2 us-gaap Short Term Investments
ShortTermInvestments
45107000
CY2017Q2 us-gaap Assets
Assets
55704000
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
331000
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1758000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7715000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
5026000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M25D
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36501000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36460000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.012 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.12
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
36104000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
41000 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.082 pure
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
356000 shares
us-gaap Revenues
Revenues
18295000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1194000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
30080000
us-gaap Operating Income Loss
OperatingIncomeLoss
7492000
us-gaap Net Income Loss
NetIncomeLoss
7615000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
124000
us-gaap Licenses Revenue
LicensesRevenue
17101000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1837000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-697000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5025000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4212000
us-gaap Share Based Compensation
ShareBasedCompensation
1411000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
25057000
us-gaap Costs And Expenses
CostsAndExpenses
10803000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4650000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1495000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4212000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3288000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4213000
us-gaap Cost Of Services
CostOfServices
2865000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8912000 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
dei Entity Central Index Key
EntityCentralIndexKey
0001262104
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11313000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
122343 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.66
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
dei Trading Symbol
TradingSymbol
MEIP
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37390000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37390000 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.44
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M19D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
252603 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
36990000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1692000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
113391 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.971 pure
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
400000 shares
us-gaap Revenues
Revenues
641000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
641000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
15038000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15059000
us-gaap Net Income Loss
NetIncomeLoss
-14867000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
193000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-986000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
504000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
10005000
us-gaap Share Based Compensation
ShareBasedCompensation
1698000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-106000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
25043000
us-gaap Costs And Expenses
CostsAndExpenses
15700000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4846000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
445000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
45000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
189000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9508000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1119000
us-gaap Cost Of Services
CostOfServices
1346000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
189000
meip Lease Arrangement Rent Area
LeaseArrangementRentArea
13700 sqft
meip Lease Commencement Month And Year
LeaseCommencementMonthAndYear
2017-06
meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00 pure
meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2020-05
meip Tax Cuts And Jobs Act Of2017 Tax Effect Accounting Complete
TaxCutsAndJobsActOf2017TaxEffectAccountingComplete
false
meip Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
13600000
CY2016Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7915000 shares
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37217000 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37172000 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
36772000 shares
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2016Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
45000 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
400000 shares
CY2016Q4 us-gaap Revenues
Revenues
17199000
CY2016Q4 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
98000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
11816000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
11885000
CY2016Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
69000
CY2016Q4 us-gaap Licenses Revenue
LicensesRevenue
17101000
CY2016Q4 us-gaap Share Based Compensation
ShareBasedCompensation
674000
CY2016Q4 us-gaap Costs And Expenses
CostsAndExpenses
5383000
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1970000
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1642000
CY2016Q4 us-gaap Cost Of Services
CostOfServices
1771000
CY2017Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8644000 shares
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37414000 shares
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37414000 shares
CY2017Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
37014000 shares
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2017Q4 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2017Q4 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
400000 shares
CY2017Q4 us-gaap Revenues
Revenues
358000
CY2017Q4 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
358000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6172000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6079000
CY2017Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
93000
CY2017Q4 us-gaap Share Based Compensation
ShareBasedCompensation
702000
CY2017Q4 us-gaap Costs And Expenses
CostsAndExpenses
6530000
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2358000
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3444000
CY2017Q4 us-gaap Cost Of Services
CostOfServices
728000

Files In Submission

Name View Source Status
0001193125-18-035521-index-headers.html Edgar Link pending
0001193125-18-035521-index.html Edgar Link pending
0001193125-18-035521.txt Edgar Link pending
0001193125-18-035521-xbrl.zip Edgar Link pending
d515603d10q.htm Edgar Link pending
d515603dex311.htm Edgar Link pending
d515603dex312.htm Edgar Link pending
d515603dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
meip-20171231.xml Edgar Link completed
meip-20171231.xsd Edgar Link pending
meip-20171231_cal.xml Edgar Link unprocessable
meip-20171231_def.xml Edgar Link unprocessable
meip-20171231_lab.xml Edgar Link unprocessable
meip-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending